Company / Capital Expenditures
Myriad Genetics, Inc. Capital Expenditures History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$45.3M
FY2022
5-year range
$18.0M / $45.3M
FY2018-FY2022
Trend
+151.7%
vs FY2021
Sector context
#28 of 194
Health Care
What the data says
Myriad Genetics, Inc.'s capital expenditures of $45M is higher than 86% of companies in the Health Care sector (FY2022). Capital Expenditures has increased for 3 consecutive years, from $6M in FY2019 to $45M in FY2022.
Based on SEC 10-K filings.
$45M in FY2022 with a 5-year CAGR of +49.3%. Top quartile in the Health Care sector.
Improved from $10M to $45M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +95.1%
- 5-Year CAGR
- +49.3%
- 10-Year CAGR
- -
Sector benchmark
-61.5% below sector average
Key checks
Key Insights
- Myriad Genetics, Inc.'s capital expenditures has grown for 3 consecutive years.
- 5-year CAGR of +49.3%, indicating consistent growth.
- In FY2022, capital expenditures increased 151.7% year-over-year.
- Ranks #28 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $45.3M | +151.7% |
| FY2021 | $18.0M | +76.5% |
| FY2020 | $10.2M | +67.2% |
| FY2019 | $6.1M | -27.4% |
| FY2018 | $8.4M | +37.7% |
| FY2017 | $6.1M | +22.0% |
| FY2016 | $5.0M | -79.1% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026